Nigeria has taken a major step in its fight against HIV/AIDS with the arrival of its first shipment of lenacapavir, a long-acting injectable drug designed to prevent HIV infection. The development marks a significant milestone in the country’s public health response and expands available options for HIV prevention.
The shipment, which arrived earlier this week, was confirmed by the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) under the Federal Ministry of Health and Social Welfare. Health authorities described the delivery as a “major advancement” in Nigeria’s efforts to reduce new HIV infections and improve access to preventive care.
Lenacapavir is a groundbreaking medication used for pre-exposure prophylaxis (PrEP), a preventive treatment for individuals who are HIV-negative but at risk of infection. Unlike traditional PrEP drugs that require daily pills, lenacapavir is administered just twice a year, making it far more convenient for users.
Health experts say this long-acting feature could significantly improve adherence, especially among populations who struggle with taking daily medication. According to officials, the drug has shown near-complete effectiveness in clinical trials, positioning it as one of the most promising tools in HIV prevention.
The procurement of the drug was approved by Nigeria’s Coordinating Minister of Health and Social Welfare and supported by international partners, including the Global Fund.
Authorities emphasized that the introduction of lenacapavir reflects Nigeria’s commitment to adopting innovative, evidence-based interventions to control the HIV epidemic. Plans are already underway for a phased rollout, with health agencies working to ensure safe distribution and proper integration into existing prevention programs.
The arrival of lenacapavir is expected to broaden prevention choices for Nigerians, particularly for vulnerable and high-risk groups. Officials note that the injectable option could help overcome barriers such as stigma, forgetfulness, and limited access to healthcare facilities, challenges often associated with daily oral PrEP.
In addition, partnerships and licensing agreements are expected to make the drug more affordable in low- and middle-income countries, including Nigeria, compared to its high cost in developed nations.
Public health experts believe the successful rollout of lenacapavir could play a critical role in Nigeria’s goal of reducing new HIV infections and eventually ending the epidemic as a public health threat.
However, stakeholders also caution that effective implementation, sustained funding, and equitable access will be key to maximizing the drug’s impact across the country.
As Nigeria begins deploying this new prevention tool, the focus now shifts to ensuring that the medication reaches those who need it most, marking the start of a new chapter in the nation’s HIV response.
Comments
Post a Comment